SGT-003 is under clinical development by Solid Biosciences and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase II drugs for Duchenne Muscular Dystrophy have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SGT-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SGT-003 overview

SGT-003 is under development for the treatment of Duchenne muscular dystrophy (DMD).  It is administered through intravenous route. It comprises of adeno associated virus delivering nNOS-containing microdystrophin.

Solid Biosciences overview

Solid Biosciences, operates as a life science company that develops therapies for duchenne muscular dystrophy (DMD). The company product pipeline includes SGT-003, AVB-202-TT and AVB-401 BAG3 DCM. Its pipeline treats duchenne, friedreich’s ataxia and mediated dilated cardiomyopathy. Biosciences has development programs across scientific platforms which include corrective therapies, disease-modifying therapies, disease understanding and assistive devices. The company works in collaboration with the University of Massachusetts Medical School, The Duchenne Research Fund, University of Washington, Alex’s Wish. It has operations across the US. Solid Biosciences is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of SGT-003’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.